How daraxonrasib impacted one pancreatic cancer patient| STAT
The approval of daraxonrasib, a new life-extending drug for pancreatic cancer, is the biggest advance in decades against…
Eli Lilly, NIH grants, Novartis, Regeneron: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
The cellular landscape of druggable RNA-binding proteins
Gerstberger, S., Hafner, M. & Tuschl, T. A census of human RNA-binding proteins. Nat. Rev. Genet. 15, 829–845…
Merck discontinues antiobiotic Recarbrio in U.S., despite superbug fears
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Health insurance premiums skyrocket, an unusual hospital deal
Bob covers the money in health care, focusing on health insurance and hospitals. His stories delve into Medicare…
GLP-1s in children, Syntis Bio, Vera: Readout Newsletter
National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways…
Chemotherapy, cancer drug shortages, drug reps: The Readout
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Kura Oncology launches diabetes-focused Caspian Therapeutics
Just under a year after netting its first US approval for a cancer-fighting menin inhibitor, Kura Oncology…
Amylyx endocrine drug succeeds in key study for low blood sugar
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
Enveda weight loss maintenance pill mimics exercise in early tests
If you could design an oral treatment that limits appetite and mimics some effects of physical activity, you…
From GLP-1 hormone to weight-loss drug: How semaglutide is made and why quality matters
What does it really take to recreate one of today’s most talked-about medicines? As semaglutide gains traction worldwide,…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…